New York State Common Retirement Fund Ngm Biopharmaceuticals Inc Transaction History

New York State Common Retirement Fund

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	SELL	$1.17 - $1.92 $23 - $38	-20 Reduced 0.19%	10,252 $16,000
Q3 2023 Nov 07, 2023	BUY	$1.05 - $3.37 $132 - $424	126 Added 1.24%	10,272 $11,000
Q1 2023 May 02, 2023	SELL	$3.72 - $5.4 $60,636 - $88,020	-16,300 Reduced 61.64%	10,146 $41,000
Q4 2022 Jan 30, 2023	SELL	$3.41 - $12.93 $54 - $206	-16 Reduced 0.06%	26,446 $133,000
Q3 2022 Nov 08, 2022	BUY	$12.59 - $17.67 $47,237 - $66,297	3,752 Added 16.52%	26,462 $346,000
Q2 2022 Aug 04, 2022	SELL	$10.58 - $17.5 $782 - $1,295	-74 Reduced 0.32%	22,710 $291,000
Q1 2022 May 05, 2022	BUY	$13.81 - $18.6 $276 - $372	20 Added 0.09%	22,784 $347,000
Q4 2021 Feb 02, 2022	SELL	$17.26 - $22.02 $1,864 - $2,378	-108 Reduced 0.47%	22,764 $403,000
Q3 2021 Nov 02, 2021	SELL	$20.15 - $26.19 $87,350 - $113,533	-4,335 Reduced 15.93%	22,872 $481,000
Q2 2021 Aug 02, 2021	BUY	$15.06 - $30.03 $78,417 - $156,366	5,207 Added 23.67%	27,207 $537,000
Q4 2019 Feb 05, 2020	BUY	$9.97 - $20.28 $150,547 - $306,228	15,100 Added 218.84%	22,000 $407,000
Q2 2019 Aug 09, 2019	BUY	$12.56 - $16.6 $86,664 - $114,540	6,900 New	6,900 $101,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on New York State Common Retirement Fund with notifications on news.